Nevirapine Generics [uk] (Nevirapine)

Nevirapine is used as part of antiretroviral therapy to inhibit HIV‑1 replication.

• HIV‑1 infection (adults): when added to a combination of nucleoside reverse transcriptase inhibitors, it lowers plasma HIV‑1 RNA levels and helps maintain immune function.
• HIV‑1 infection (children): incorporated into pediatric antiretroviral regimens, it contributes to sustained viral suppression and CD4 count improvement.
• Treatment‑experienced HIV‑1 infection: offers an alternative NNRTI backbone for patients who have experienced virologic failure with other agents.
• HIV‑1 infection (initial therapy): recommended as part of a first‑line regimen combined with two nucleoside reverse transcriptase inhibitors to achieve early viral suppression.

• Nevirapine binds to a hydrophobic pocket on the HIV‑1 reverse transcriptase enzyme that is distinct from the nucleoside binding site. This binding induces a conformational change that impairs the enzyme’s polymerase activity, preventing the conversion of viral RNA into DNA and thereby halting viral replication in infected cells.

Nevirapine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Rash: mild to moderate skin redness, often transient.
• Nausea: feeling of stomach upset, may be accompanied by vomiting.
• Fatigue: generalized tiredness that can affect daily activities.
• Headache: mild to moderate pain in the head region.
• Abdominal pain: discomfort or cramping in the stomach area.
• Dizziness: sensation of light‑headedness or unsteadiness.

Serious or Rare Side Effects

• Stevens‑Johnson syndrome or toxic epidermal necrolysis: severe skin reactions with blistering and detachment.
• Severe hepatic injury or hepatitis: marked elevation of liver enzymes, jaundice, or liver failure.
• Hypersensitivity reactions with fever and eosinophilia: systemic allergic response requiring immediate discontinuation.
• Neutropenia or severe anemia: significant reduction in white blood cells or red blood cells.
• Grade 3–4 elevated liver enzymes: substantial increase in ALT/AST indicating liver stress.
• Drug‑induced lung injury: rare pulmonary toxicity presenting with cough and dyspnea.

When prescribing nevirapine, clinicians should observe several safety precautions to minimize risk.

• Liver monitoring: check baseline hepatic enzymes and repeat regularly during therapy.
• Rash surveillance: inspect skin frequently and discontinue if severe rash develops.
• Hypersensitivity watch: be alert for fever, malaise, or eosinophilia indicating allergic reaction.
• Drug interactions: avoid co‑administration with strong CYP3A4 inducers that lower nevirapine levels.
• Pregnancy considerations: use only if benefits outweigh potential risks, after specialist assessment.
• Store at ambient temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Nevirapine interacts with several medicines; understanding the interaction level guides clinical management.

Major Interactions (Avoid)

• Rifampicin: induces CYP3A4, markedly reducing nevirapine exposure.
• St. John’s wort: strong CYP3A4 inducer that can lead to therapeutic failure.
• Protease inhibitors (e.g., ritonavir): increase nevirapine levels and risk of hepatotoxicity.
• Carbamazepine: enzyme inducer that lowers nevirapine concentrations.
• Efavirenz: concurrent NNRTIs can cause additive toxicity.

Moderate Interactions (Monitor Closely)

• Azole antifungals (ketoconazole, fluconazole): may increase nevirapine plasma levels.
• Macrolide antibiotics (erythromycin, clarithromycin): can affect metabolism modestly.
• Oral contraceptives: nevirapine may reduce hormonal efficacy, requiring backup contraception.
• Warfarin: potential alteration of anticoagulant effect, monitor INR.
• Methadone: nevirapine may lower methadone levels, assess withdrawal symptoms.